# 4D Molecular Therapeutics, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/4D Molecular Therapeutics, Inc.).

## Overview

4D Molecular Therapeutics, Inc. is a U.S. clinical-stage genetic medicines company developing adeno-associated virus (AAV) vector-based therapies designed for durable, disease-targeted expression after a single administration. Its near-term value is concentrated in 4D-150, an intravitreal gene therapy candidate for retinal vascular diseases (wet AMD and DME) that uses an R100 vector and a transgene cassette encoding aflibercept plus an inhibitory miRNA targeting VEGF-C. A second prioritized program, 4D-710, targets cystic fibrosis by delivering the CFTR transgene to the lung and is being advanced through the AEROW clinical trial. The company funds operations primarily through equity financings and, to a lesser extent, collaboration and license arrangements, including an APAC partnership with Otsuka for 4D-150.

## Products & services

• 4D-150 gene therapy (wet AMD; DME) using R100 vector
• 4FRONT-1 and 4FRONT-2 Phase 3 clinical development (4D-150)
• 4D-710 CFTR gene therapy for cystic fibrosis (AEROW trial)
• Pipeline programs for partnering (4D-175, 4D-725, 4D-310)
• AAV vector platform and R100 capsid engineering know-how

- **Ophthalmology gene therapy (4D-150)** (55%) — Intravitreal AAV gene therapy programs for retinal vascular diseases, led by 4D-150 in wet AMD and DME.
- **Pulmonology gene therapy (4D-710)** (20%) — Inhaled/lung-delivered genetic medicine programs focused on cystic fibrosis via CFTR transgene delivery.
- **Partnered/strategic alternative pipeline (4D-175, 4D-725, 4D-310)** (10%) — Non-prioritized clinical-stage programs intended for partnering or other strategic alternatives across GA, AATD, and Fabry cardiomyopathy.
- **Platform, IP and collaborations** (15%) — AAV capsid/vector platform capabilities and monetization via collaboration, licensing, milestones and royalties.

- 4D-150 gene therapy (wet AMD; DME) using R100 vector
- 4FRONT-1 and 4FRONT-2 Phase 3 clinical development (4D-150)
- 4D-710 CFTR gene therapy for cystic fibrosis (AEROW trial)
- Pipeline programs for partnering (4D-175, 4D-725, 4D-310)
- AAV vector platform and R100 capsid engineering know-how

## Customers

As a pre-commercial biotechnology company, 4D Molecular Therapeutics’ near-term “customers” are primarily partners and funding counterparties that provide upfront payments, cost sharing, milestones, and potential royalties tied to development and commercialization outcomes. The Otsuka collaboration makes Otsuka a key customer-like counterparty for 4D-150 in Japan, China, Australia and other APAC markets, while 4DMT retains rights outside APAC. Disease-area stakeholders—retina specialists, pulmonologists, hospitals/infusion or procedure sites, and payors—are the ultimate downstream adopters if products are approved, with adoption driven by durability, safety, and reduction in treatment burden versus established therapies. Clinical trial sites and investigators are also critical operational “customers” in the sense that enrollment and execution determine timelines and data quality. Over time, the business model is expected to shift toward product sales (outside partnered territories) plus royalties in partnered regions.

- **Pharmaceutical partners (regional licensing)** (primary) — License rights to develop/commercialize programs in specific territories (e.g., 4D-150 in APAC) in exchange for upfront cash, cost sharing, milestones and royalties.
- **Non-dilutive funders and disease foundations** (secondary) — Provide program-specific funding (e.g., CF Foundation support for AEROW Phase 2 start, redosing and Phase 3 readiness) to accelerate development and de-risk trials.
- **Ophthalmology providers and patients (wet AMD/DME)** (primary) — Would adopt 4D-150 if approved to reduce injection frequency and maintain vision outcomes with sustained intraocular anti-VEGF expression.
- **Pulmonology/CF centers and patients** (emerging) — Would use 4D-710 if approved to address CFTR deficiency with durable lung expression and potential functional improvements.

- Pharma partners (e.g., Otsuka) seeking regional rights and royalties
- Foundations/non-dilutive funders (e.g., Cystic Fibrosis Foundation)
- Retina specialists and clinics seeking longer-lasting anti-VEGF options
- Cystic fibrosis care centers seeking durable CFTR expression therapies
- Payors evaluating total cost of care and treatment burden reduction
- Clinical trial sites/investigators enabling enrollment and execution

## Geography

4D Molecular Therapeutics is headquartered in the United States and runs clinical development across multiple geographies through global trial execution and third-party vendors. The 4FRONT-2 Phase 3 trial for wet AMD is described as global, implying multi-region enrollment and regulatory coordination. Commercial rights for 4D-150 are split by territory: Otsuka holds exclusive rights in Japan, China, Australia and other APAC markets, while 4DMT retains rights in the U.S., Europe and Latin America. This footprint creates region-specific regulatory, reimbursement, and partner-execution dependencies, particularly in APAC where commercialization is delegated to Otsuka. No authoritative revenue-by-geography percentages were provided in the available excerpts, so a quantitative geographic revenue breakdown is not presented.

- United States base for corporate operations and retained 4D-150 rights
- Global clinical trial execution (e.g., 4FRONT-2) affects timelines
- APAC (Japan, China, Australia, other markets) licensed to Otsuka
- Europe and Latin America retained by 4DMT for 4D-150 commercialization
- China exposure is primarily via partner-led commercialization/regulatory

## Strategy

Management’s stated direction is a pipeline prioritization that concentrates resources on 4D-150 (retinal vascular diseases) and 4D-710 (cystic fibrosis) to maximize probability-adjusted value and streamline execution. For other clinical-stage assets (4D-175, 4D-725, 4D-310), the company is pursuing strategic alternatives such as partnering, while discontinuing certain ophthalmology programs (4D-110 and 4D-125). The Otsuka agreement for APAC rights to 4D-150 provides non-dilutive capital, potential milestones, and a commercialization pathway in key Asian markets while 4DMT continues to lead global Phase 3 development. For 4D-710, the CF Foundation funding supports progression into Phase 2 activities, redosing, and Phase 3 readiness work, aiming to accelerate clinical proof-of-concept and regulatory path clarity.

- **Execute Phase 3 development of 4D-150 in wet AMD and DME** (medium-term) — Late-stage data and regulatory submissions are the main catalysts for value creation and future commercialization outside partnered territories.
- **Advance 4D-710 through AEROW and prepare for later-stage trials** (short-term) — Demonstrating durable CFTR expression and clinical benefit would differentiate the program and support partnering or pivotal development.
- **Monetize non-prioritized pipeline via partnering/strategic alternatives** (short-term) — Partnerships can extend runway and preserve optionality while focusing internal resources on the two priority programs.

- Prioritize 4D-150 to drive late-stage ophthalmology value creation
- Advance 4D-710 with staged clinical updates and Phase 3 readiness work
- Seek partners/strategic alternatives for non-core clinical programs
- Use regional licensing (Otsuka APAC) to fund development and de-risk
- Reduce burn by terminating lower-priority programs (4D-110, 4D-125)

## Risks

The company has no approved products and is dependent on clinical trial success and regulatory approvals, making outcomes highly sensitive to efficacy, safety, and trial execution in late-stage studies for 4D-150 and earlier-stage work for 4D-710. Competitive risk is significant because wet AMD/DME and cystic fibrosis have established therapies and well-funded competitors, which can raise the bar for differentiation and payer/physician switching. Manufacturing risk is elevated because gene therapies are complex to produce; production issues can delay trials, constrain supply, or increase costs. Partnering risk is also material: collaborations may not progress efficiently, and termination or underperformance by partners (e.g., in licensed territories) can reduce expected milestones/royalties and slow commercialization. Financing risk remains inherent given reliance on equity issuance and external funding to sustain multi-year development timelines.

- **No approved products; limited operating history and late-stage development dependence** [critical] — Business viability depends on successful completion of trials and approvals, which are uncertain and can materially change valuation and funding access.
- **Gene therapy manufacturing is novel, complex and difficult** [high] — Production problems can delay development/commercialization and limit supply, directly impacting timelines and costs.
- **Collaboration agreements may not deliver efficient development or may terminate** [medium] — Partner decisions and integration challenges can reduce expected milestones/royalties and slow regional commercialization.

- Clinical failure or safety signals could derail 4D-150/4D-710 programs
- Late-stage trial execution risk (enrollment, endpoints, comparability)
- Gene therapy manufacturing complexity may cause delays or shortages
- Strong incumbents in wet AMD/DME and CF may limit adoption/pricing
- Partner execution/termination risk in collaborations (e.g., APAC rights)
- Regulatory uncertainty for novel gene therapies and trial designs
- Ongoing need for capital; equity dilution risk if funding tightens

## Accounting

As a development-stage biotech, reported results are heavily influenced by management estimates and judgments in accruals for R&D activities conducted through CROs and CMOs, where the timing and completion of services can make period-to-period expense recognition volatile. Collaboration and license arrangements can introduce complex revenue recognition and classification questions (e.g., upfront payments, cost-sharing reimbursements, milestones, and royalties), which may be recognized at different times depending on contract terms and performance obligations. The company also highlights commitments under vendor contracts that are often cancellable with termination provisions, making the magnitude and timing of future cash outflows uncertain and requiring judgment in disclosure and accruals. Operating leases for headquarters are a principal commitment, so lease accounting affects right-of-use assets, lease liabilities, and operating expense presentation. Overall, investors should focus on how estimates for clinical trial accruals, collaboration accounting, and contingent commitments drive quarterly variability rather than interpreting short-term fluctuations as underlying demand signals.

- **R&D accruals for CRO/CMO and clinical trial activities** — Can materially shift operating expense between quarters without changing program progress.
- **Collaboration and license arrangement accounting (upfronts, milestones, royalties, cost sharing)** — Non-linear revenue/other income recognition and presentation can affect headline results.
- **Operating leases for headquarters** — Changes balance sheet leverage optics and operating expense profile.

- R&D accrual estimates for CRO/CMO services drive quarterly volatility
- Collaboration payments (upfront/milestones/royalties) timing is judgmental
- Cost-sharing and reimbursements classification affects reported revenue/expense
- Commitments are often cancellable; disclosure vs accrual requires judgment
- Operating lease accounting impacts ROU assets, lease liabilities, opex

---

*Last updated: 2026-08-11T04:46:16.788063+00:00*